Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir in Congenital CMV
NCT00001100Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ganciclovir in congenital cytomegalovirus infection (cCMV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Degree of improved hearing among surviving patients at 2 years. Status: completed.
02
Drugs
ganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT00001100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001100.